Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by MrMugsyon Jan 17, 2021 10:38pm
302 Views
Post# 32317056

RE:RE:RE:Just reading about recent acquisition when suddenly..

RE:RE:RE:Just reading about recent acquisition when suddenly..
Pragmatist wrote:
MrMugsy wrote: A buyout would be great but regardless ... the value of ATE will eventually come through if you're a believer.  Good companies always hit higher highs - it's just hard to call the dates when people get uber-excited.

ATE is suely creating options for OTENA and for their other drugs.  Multiple pathways is the key to showing potential partners that ATE is in the driver's seat.

Also keep in mind that if ATE is likely already working with Big Pharma on COVID collaboration (as per Dan's inability to discuss the topic).

With any luck, the COVID work will help instill the value of these H2S patents and demonstrate first-hand how H2S may be valuable in blocking viral cell entry, inhibiting viral replication and/or supressing inflammation in the lungs.

I can wait for the excitement.  Not the first time I have to wait for shareholders to figure it out.  IMO.

 

That is a good thought, Mugsy. 
 
It is common for suitors to start a relationship with a small biotech with a partnering/collaboration deal, and then acquire the company at a later stage of development.  As one CEO put it, partnering is almost always the lead in to an acquisition.
 


Thank you.  I was waiting for Dan to announce a collaboration (since the last letter to shareholders).  Then finally realized ... COVID was probably the collaboration he was eluding to.  Will see.
<< Previous
Bullboard Posts
Next >>